{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:44:39Z","timestamp":1792687479279,"version":"4.5.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":685,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["U54NS065712"],"award-info":[{"award-number":["U54NS065712"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS102509"],"award-info":[{"award-number":["NS102509"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005339","name":"American Academy of Neurology","doi-asserted-by":"crossref","award":["0078966\/129168"],"award-info":[{"award-number":["0078966\/129168"]}],"id":[{"id":"10.13039\/100005339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13311-021-01099-2","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T23:39:57Z","timestamp":1633390797000},"page":"2269-2285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-9728","authenticated-orcid":false,"given":"Brett A.","family":"McCray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01099-2_bib1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/jnnp-2016-313960","article-title":"Peripheral neuropathy in complex inherited diseases: an approach to diagnosis","volume":"88","author":"Rossor","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01099-2_bib2","doi-asserted-by":"crossref","unstructured":"Scherer, S. S., Kleopa, K. A. & Benson, M. D. Rosenberg's molecular and genetic basis of neurological and psychiatric disease. 6th edn, Vol. 2 345\u201376 (Academic Press, 2020).","DOI":"10.1016\/B978-0-12-813866-3.00021-7"},{"key":"10.1007\/s13311-021-01099-2_bib3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/jmg.17.5.329","article-title":"Genetic aspects of hereditary motor and sensory neuropathy (types I and II)","volume":"17","author":"Harding","year":"1980","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-021-01099-2_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1399-0004.1974.tb00638.x","article-title":"Genetic and clinical aspects of Charcot-Marie-Tooth's disease","volume":"6","author":"Skre","year":"1974","journal-title":"Clin Genet"},{"key":"10.1007\/s13311-021-01099-2_bib5","doi-asserted-by":"crossref","unstructured":"Barreto, L. C., Oliveira, F. S., Nunes, P. S., de Franca Costa, I. M., Garcez, C. A., Goes, G. M., Neves, E. L., de Souza Siqueira Quintans, J. & de Souza Araujo, A. A. Epidemiologic Study of Charcot-Marie-Tooth Disease: A Systematic Review. Neuroepidemiology46, 157\u2013165 (2016).","DOI":"10.1159\/000443706"},{"key":"10.1007\/s13311-021-01099-2_bib6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/B978-0-444-52902-2.00047-3","article-title":"Dominant Charcot-Marie-Tooth syndrome and cognate disorders","volume":"115","author":"Pareyson","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-021-01099-2_bib7","doi-asserted-by":"crossref","unstructured":"Bis-Brewer, D. M., Fazal, S. & Zuchner, S. Genetic modifiers and non-Mendelian aspects of CMT. Brain Res1726, 146459 (2020).","DOI":"10.1016\/j.brainres.2019.146459"},{"key":"10.1007\/s13311-021-01099-2_bib8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/WCO.0000000000000735","article-title":"Charcot-Marie-Tooth disease and related disorders: an evolving landscape","volume":"32","author":"Laura","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-021-01099-2_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1385\/NMM:8:1-2:43","article-title":"Molecular genetics of autosomal-dominant demyelinating Charcot-Marie-Tooth disease","volume":"8","author":"Houlden","year":"2006","journal-title":"Neuromolecular Med"},{"key":"10.1007\/s13311-021-01099-2_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3233\/JND-190427","article-title":"Defects in Axonal Transport in Inherited Neuropathies","volume":"6","author":"Beijer","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.1007\/s13311-021-01099-2_bib11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41582-019-0257-2","article-title":"Axonal transport and neurological disease","volume":"15","author":"Sleigh","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-021-01099-2_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrn2631","article-title":"Microtubule assembly, organization and dynamics in axons and dendrites","volume":"10","author":"Conde","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"10.1007\/s13311-021-01099-2_bib13","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajhg.2013.04.011","article-title":"Mutations in BICD2, which encodes a golgin and important motor adaptor, cause congenital autosomal-dominant spinal muscular atrophy","volume":"92","author":"Neveling","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-021-01099-2_bib14","doi-asserted-by":"crossref","unstructured":"Oates, E. C., Rossor, A. M., Hafezparast, M., Gonzalez, M., Speziani, F., MacArthur, D. G., Lek, M., Cottenie, E., Scoto, M., Foley, A. R., Hurles, M., Houlden, H., Greensmith, L., Auer-Grumbach, M., Pieber, T. R., Strom, T. M., Schule, R., Herrmann, D. N., Sowden, J. E., Acsadi, G., Menezes, M. P., Clarke, N. F., Zuchner, S., Uk10K, Muntoni, F., North, K. N. & Reilly, M. M. Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic paraplegia. Am J Hum Genet92, 965\u2013973 (2013).","DOI":"10.1016\/j.ajhg.2013.04.018"},{"key":"10.1007\/s13311-021-01099-2_bib15","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ajhg.2013.04.013","article-title":"Molecular defects in the motor adaptor BICD2 cause proximal spinal muscular atrophy with autosomal-dominant inheritance","volume":"92","author":"Peeters","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-021-01099-2_bib16","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1086\/367847","article-title":"Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy","volume":"72","author":"Verhoeven","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-021-01099-2_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng1123","article-title":"Mutant dynactin in motor neuron disease","volume":"33","author":"Puls","year":"2003","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-021-01099-2_bib18","doi-asserted-by":"crossref","unstructured":"Hafezparast, M., Klocke, R., Ruhrberg, C., Marquardt, A., Ahmad-Annuar, A., Bowen, S., Lalli, G., Witherden, A. S., Hummerich, H., Nicholson, S., Morgan, P. J., Oozageer, R., Priestley, J. V., Averill, S., King, V. R., Ball, S., Peters, J., Toda, T., Yamamoto, A., Hiraoka, Y., Augustin, M., Korthaus, D., Wattler, S., Wabnitz, P., Dickneite, C., Lampel, S., Boehme, F., Peraus, G., Popp, A., Rudelius, M., Schlegel, J., Fuchs, H., Hrabe de Angelis, M., Schiavo, G., Shima, D. T., Russ, A. P., Stumm, G., Martin, J. E. & Fisher, E. M. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science300, 808\u2013812 (2003).","DOI":"10.1126\/science.1083129"},{"key":"10.1007\/s13311-021-01099-2_bib19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ajhg.2011.07.002","article-title":"Exome sequencing identifies a DYNC1H1 mutation in a large pedigree with dominant axonal Charcot-Marie-Tooth disease","volume":"89","author":"Weedon","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-021-01099-2_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ajhg.2011.06.013","article-title":"KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2","volume":"89","author":"Riviere","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-021-01099-2_bib21","doi-asserted-by":"crossref","unstructured":"Nicolas, A., Kenna, K. P., Renton, A. E., Ticozzi, N., Faghri, F., Chia, R., Dominov, J. A., Kenna, B. J., Nalls, M. A., Keagle, P., Rivera, A. M., van Rheenen, W., Murphy, N. A., van Vugt, J., Geiger, J. T., Van der Spek, R. A., Pliner, H. A., Shankaracharya, Smith, B. N., Marangi, G., Topp, S. D., Abramzon, Y., Gkazi, A. S., Eicher, J. D., Kenna, A., Consortium, I., Mora, G., Calvo, A., Mazzini, L., Riva, N., Mandrioli, J., Caponnetto, C., Battistini, S., Volanti, P., La Bella, V., Conforti, F. L., Borghero, G., Messina, S., Simone, I. L., Trojsi, F., Salvi, F., Logullo, F. O., D'Alfonso, S., Corrado, L., Capasso, M., Ferrucci, L., Genomic Translation for, A. L. S. C. C., Moreno, C. A. M., Kamalakaran, S., Goldstein, D. B., Consortium, A. L. S. S., Gitler, A. D., Harris, T., Myers, R. M., Consortium, N. A., Phatnani, H., Musunuri, R. L., Evani, U. S., Abhyankar, A., Zody, M. C., Answer, A. L. S. F., Kaye, J., Finkbeiner, S., Wyman, S. K., LeNail, A., Lima, L., Fraenkel, E., Svendsen, C. N., Thompson, L. M., Van Eyk, J. E., Berry, J. D., Miller, T. M., Kolb, S. J., Cudkowicz, M., Baxi, E., Clinical Research in, A. L. S., Related Disorders for Therapeutic Development, C., Benatar, M., Taylor, J. P., Rampersaud, E., Wu, G., Wuu, J., Consortium, S., Lauria, G., Verde, F., Fogh, I., Tiloca, C., Comi, G. P., Soraru, G., Cereda, C., French, A. L. S. C., Corcia, P., Laaksovirta, H., Myllykangas, L., Jansson, L., Valori, M., Ealing, J., Hamdalla, H., Rollinson, S., Pickering-Brown, S., Orrell, R. W., Sidle, K. C., Malaspina, A., Hardy, J., Singleton, A. B., Johnson, J. O., Arepalli, S., Sapp, P. C., McKenna-Yasek, D., Polak, M., Asress, S., Al-Sarraj, S., King, A., Troakes, C., Vance, C., de Belleroche, J., Baas, F., Ten Asbroek, A., Munoz-Blanco, J. L., Hernandez, D. G., Ding, J., Gibbs, J. R., Scholz, S. W., Floeter, M. K., Campbell, R. H., Landi, F., Bowser, R., Pulst, S. M., Ravits, J. M., MacGowan, D. J. L., Kirby, J., Pioro, E. P., Pamphlett, R., Broach, J., Gerhard, G., Dunckley, T. L., Brady, C. B., Kowall, N. W., Troncoso, J. C., Le Ber, I., Mouzat, K., Lumbroso, S., Heiman-Patterson, T. D., Kamel, F., Van Den Bosch, L., Baloh, R. H., Strom, T. M., Meitinger, T., Shatunov, A., Van Eijk, K. R., de Carvalho, M., Kooyman, M., Middelkoop, B., Moisse, M., McLaughlin, R. L., Van Es, M. A., Weber, M., Boylan, K. B., Van Blitterswijk, M., Rademakers, R., Morrison, K. E., Basak, A. N., Mora, J. S., Drory, V. E., Shaw, P. J., Turner, M. R., Talbot, K., Hardiman, O., Williams, K. L., Fifita, J. A., Nicholson, G. A., Blair, I. P., Rouleau, G. A., Esteban-Perez, J., Garcia-Redondo, A., Al-Chalabi, A., Project Min, E. A. L. S. S. C., Rogaeva, E., Zinman, L., Ostrow, L. W., Maragakis, N. J., Rothstein, J. D., Simmons, Z., Cooper-Knock, J., Brice, A., Goutman, S. A., Feldman, E. L., Gibson, S. B., Taroni, F., Ratti, A., Gellera, C., Van Damme, P., Robberecht, W., Fratta, P., Sabatelli, M., Lunetta, C., Ludolph, A. C., Andersen, P. M., Weishaupt, J. H., Camu, W., Trojanowski, J. Q., Van Deerlin, V. M., Brown, R. H., Jr., van den Berg, L. H., Veldink, J. H., Harms, M. B., Glass, J. D., Stone, D. J., Tienari, P., Silani, V., Chio, A., Shaw, C. E., Traynor, B. J. & Landers, J. E. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron97, 1268\u20131283 e1266 (2018).","DOI":"10.2139\/ssrn.3155776"},{"key":"10.1007\/s13311-021-01099-2_bib22","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1212\/WNL.0000000000000691","article-title":"Extended phenotypic spectrum of KIF5A mutations: From spastic paraplegia to axonal neuropathy","volume":"83","author":"Liu","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01099-2_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1399-0004.2011.01717.x","article-title":"Mutations in the motor and stalk domains of KIF5A in spastic paraplegia type 10 and in axonal Charcot-Marie-Tooth type 2","volume":"82","author":"Crimella","year":"2012","journal-title":"Clin Genet"},{"key":"10.1007\/s13311-021-01099-2_bib24","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/ncb2127","article-title":"A cytoplasmic dynein tail mutation impairs motor processivity","volume":"12","author":"Ori-McKenney","year":"2010","journal-title":"Nat Cell Biol"},{"key":"10.1007\/s13311-021-01099-2_bib25","doi-asserted-by":"crossref","unstructured":"Staff, N. P., Fehrenbacher, J. C., Caillaud, M., Damaj, M. I., Segal, R. A. & Rieger, S. Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol324, 113121 (2020).","DOI":"10.1016\/j.expneurol.2019.113121"},{"key":"10.1007\/s13311-021-01099-2_bib26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp-2017-317215","article-title":"Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort","volume":"89","author":"Shah","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01099-2_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neuro.2013.05.008","article-title":"Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy","volume":"37","author":"LaPointe","year":"2013","journal-title":"Neurotoxicology"},{"key":"10.1007\/s13311-021-01099-2_bib28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-009-0586-0","article-title":"Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy","volume":"119","author":"Shemesh","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-021-01099-2_bib29","doi-asserted-by":"crossref","unstructured":"Chauvenet, A. R., Shashi, V., Selsky, C., Morgan, E., Kurtzberg, J., Bell, B. & Pediatric Oncology Group, S. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol25, 316\u2013320 (2003).","DOI":"10.1097\/00043426-200304000-00010"},{"key":"10.1007\/s13311-021-01099-2_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/0284186X.2017.1415462","article-title":"Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability","volume":"57","author":"Ibanez-Julia","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1007\/s13311-021-01099-2_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neulet.2015.04.001","article-title":"Mitochondrial dynamics and inherited peripheral nerve diseases","volume":"596","author":"Pareyson","year":"2015","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-021-01099-2_bib32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.20797","article-title":"Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2","volume":"59","author":"Zuchner","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01099-2_bib33","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1212\/WNL.0b013e31821a441e","article-title":"MFN2 mutations cause severe phenotypes in most patients with CMT2A","volume":"76","author":"Feely","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01099-2_bib34","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s00415-011-5910-7","article-title":"Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2","volume":"258","author":"McCorquodale","year":"2011","journal-title":"J Neurol"},{"key":"10.1007\/s13311-021-01099-2_bib35","doi-asserted-by":"crossref","unstructured":"Pipis, M., Feely, S. M. E., Polke, J. M., Skorupinska, M., Perez, L., Shy, R. R., Laura, M., Morrow, J. M., Moroni, I., Pisciotta, C., Taroni, F., Vujovic, D., Lloyd, T. E., Acsadi, G., Yum, S. W., Lewis, R. A., Finkel, R. S., Herrmann, D. N., Day, J. W., Li, J., Saporta, M., Sadjadi, R., Walk, D., Burns, J., Muntoni, F., Ramchandren, S., Horvath, R., Johnson, N. E., Zuchner, S., Pareyson, D., Scherer, S. S., Rossor, A. M., Shy, M. E., Reilly, M. M. & Inherited Neuropathies Consortium - Rare Disease Clinical Research, N. Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. Brain143, 3589\u20133602 (2020).","DOI":"10.1093\/brain\/awaa323"},{"key":"10.1007\/s13311-021-01099-2_bib36","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.1099793","article-title":"Structural basis of mitochondrial tethering by mitofusin complexes","volume":"305","author":"Koshiba","year":"2004","journal-title":"Science"},{"key":"10.1007\/s13311-021-01099-2_bib37","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1523\/JNEUROSCI.6248-09.2010","article-title":"Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro\/Milton complex","volume":"30","author":"Misko","year":"2010","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01099-2_bib38","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1212\/WNL.0b013e318228fc70","article-title":"Dominant GDAP1 mutations cause predominantly mild CMT phenotypes","volume":"77","author":"Zimon","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01099-2_bib39","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archneur.60.4.598","article-title":"Phenotypical features of a Moroccan family with autosomal recessive Charcot-Marie-Tooth disease associated with the S194X mutation in the GDAP1 gene","volume":"60","author":"Birouk","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-021-01099-2_bib40","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s10038-008-0249-3","article-title":"A novel GDAP1 Q218E mutation in autosomal dominant Charcot-Marie-Tooth disease","volume":"53","author":"Chung","year":"2008","journal-title":"J Hum Genet"},{"key":"10.1007\/s13311-021-01099-2_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/79944","article-title":"OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28","volume":"26","author":"Alexander","year":"2000","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-021-01099-2_bib42","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/brain\/awq007","article-title":"Multi-system neurological disease is common in patients with OPA1 mutations","volume":"133","author":"Yu-Wai-Man","year":"2010","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01099-2_bib43","doi-asserted-by":"crossref","unstructured":"Horga, A., Bugiardini, E., Manole, A., Bremner, F., Jaunmuktane, Z., Dankwa, L., Rebelo, A. P., Woodward, C. E., Hargreaves, I. P., Cortese, A., Pittman, A. M., Brandner, S., Polke, J. M., Pitceathly, R. D. S., Zuchner, S., Hanna, M. G., Scherer, S. S., Houlden, H. & Reilly, M. M. Autosomal dominant optic atrophy and cataract \u201cplus\u201d phenotype including axonal neuropathy. Neurol Genet5, e322 (2019).","DOI":"10.1212\/NXG.0000000000000322"},{"key":"10.1007\/s13311-021-01099-2_bib44","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1474-4422(13)70158-3","article-title":"Peripheral neuropathy in mitochondrial disorders","volume":"12","author":"Pareyson","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01099-2_bib45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.neurol.2013.11.005","article-title":"Inherited peripheral neuropathies due to mitochondrial disorders","volume":"170","author":"Cassereau","year":"2014","journal-title":"Rev Neurol (Paris)"},{"key":"10.1007\/s13311-021-01099-2_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jns.2015.05.033","article-title":"MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives","volume":"356","author":"Stuppia","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-021-01099-2_bib47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1083\/jcb.200611080","article-title":"Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations","volume":"176","author":"Detmer","year":"2007","journal-title":"J Cell Biol"},{"key":"10.1007\/s13311-021-01099-2_bib48","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3389\/fphys.2020.00782","article-title":"2nd Mitofusin 2 Dysfunction and Disease in Mice and Men","volume":"11","author":"Dorn","year":"2020","journal-title":"Front Physiol"},{"key":"10.1007\/s13311-021-01099-2_bib49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1523\/JNEUROSCI.4798-06.2007","article-title":"Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations","volume":"27","author":"Baloh","year":"2007","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01099-2_bib50","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1523\/JNEUROSCI.6338-11.2012","article-title":"Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration","volume":"32","author":"Misko","year":"2012","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01099-2_bib51","doi-asserted-by":"crossref","unstructured":"Rocha, A. G., Franco, A., Krezel, A. M., Rumsey, J. M., Alberti, J. M., Knight, W. C., Biris, N., Zacharioudakis, E., Janetka, J. W., Baloh, R. H., Kitsis, R. N., Mochly-Rosen, D., Townsend, R. R., Gavathiotis, E. & Dorn, G. W., 2nd. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science360, 336\u2013341 (2018).","DOI":"10.1126\/science.aao1785"},{"key":"10.1007\/s13311-021-01099-2_bib52","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/hmg\/ddz008","article-title":"MFN2 mutations in Charcot-Marie-Tooth disease alter mitochondria-associated ER membrane function but do not impair bioenergetics","volume":"28","author":"Larrea","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-021-01099-2_bib53","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1086\/375039","article-title":"Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V","volume":"72","author":"Antonellis","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-021-01099-2_bib54","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/ng1727","article-title":"Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy","volume":"38","author":"Jordanova","year":"2006","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-021-01099-2_bib55","doi-asserted-by":"crossref","unstructured":"Safka Brozkova, D., Deconinck, T., Griffin, L. B., Ferbert, A., Haberlova, J., Mazanec, R., Lassuthova, P., Roth, C., Pilunthanakul, T., Rautenstrauss, B., Janecke, A. R., Zavadakova, P., Chrast, R., Rivolta, C., Zuchner, S., Antonellis, A., Beg, A. A., De Jonghe, P., Senderek, J., Seeman, P. & Baets, J. Loss of function mutations in HARS cause a spectrum of inherited peripheral neuropathies. Brain138, 2161\u20132172 (2015).","DOI":"10.1093\/brain\/awv158"},{"key":"10.1007\/s13311-021-01099-2_bib56","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/brain\/awx058","article-title":"A recurrent WARS mutation is a novel cause of autosomal dominant distal hereditary motor neuropathy","volume":"140","author":"Tsai","year":"2017","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01099-2_bib57","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ajhg.2010.09.008","article-title":"Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy","volume":"87","author":"McLaughlin","year":"2010","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-021-01099-2_bib58","doi-asserted-by":"crossref","unstructured":"Gonzalez, M., McLaughlin, H., Houlden, H., Guo, M., Yo-Tsen, L., Hadjivassilious, M., Speziani, F., Yang, X. L., Antonellis, A., Reilly, M. M., Zuchner, S. & Inherited Neuropathy, C. Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J Neurol Neurosurg Psychiatry84, 1247\u20131249 (2013).","DOI":"10.1136\/jnnp-2013-305049"},{"key":"10.1007\/s13311-021-01099-2_bib59","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/1873-3468.12962","article-title":"The role of tRNA synthetases in neurological and neuromuscular disorders","volume":"592","author":"Boczonadi","year":"2018","journal-title":"FEBS Lett"},{"key":"10.1007\/s13311-021-01099-2_bib60","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/humu.21635","article-title":"A recurrent loss-of-function alanyl-tRNA synthetase (AARS) mutation in patients with Charcot-Marie-Tooth disease type 2N (CMT2N)","volume":"33","author":"McLaughlin","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1007\/s13311-021-01099-2_bib61","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.mcn.2010.11.006","article-title":"An assessment of mechanisms underlying peripheral axonal degeneration caused by aminoacyl-tRNA synthetase mutations","volume":"46","author":"Stum","year":"2011","journal-title":"Mol Cell Neurosci"},{"key":"10.1007\/s13311-021-01099-2_bib62","doi-asserted-by":"crossref","first-page":"11239","DOI":"10.1073\/pnas.0705055104","article-title":"Charcot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect","volume":"104","author":"Nangle","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01099-2_bib63","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1021\/bi200989h","article-title":"Dominant Intermediate Charcot-Marie-Tooth disorder is not due to a catalytic defect in tyrosyl-tRNA synthetase","volume":"50","author":"Froelich","year":"2011","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-021-01099-2_bib64","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1073\/pnas.0703908104","article-title":"Long-range structural effects of a Charcot-Marie-Tooth disease-causing mutation in human glycyl-tRNA synthetase","volume":"104","author":"Xie","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01099-2_bib65","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nature15510","article-title":"CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase","volume":"526","author":"He","year":"2015","journal-title":"Nature"},{"key":"10.1007\/s13311-021-01099-2_bib66","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1038\/ncomms8520","article-title":"Impaired protein translation in Drosophila models for Charcot-Marie-Tooth neuropathy caused by mutant tRNA synthetases","volume":"6","author":"Niehues","year":"2015","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-021-01099-2_bib67","doi-asserted-by":"crossref","first-page":"E4859","DOI":"10.1073\/pnas.1701078114","article-title":"Contacts between the endoplasmic reticulum and other membranes in neurons","volume":"114","author":"Wu","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01099-2_bib68","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nature22369","article-title":"Applying systems-level spectral imaging and analysis to reveal the organelle interactome","volume":"546","author":"Valm","year":"2017","journal-title":"Nature"},{"key":"10.1007\/s13311-021-01099-2_bib69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrm.2015.8","article-title":"Structure and function of ER membrane contact sites with other organelles","volume":"17","author":"Phillips","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1007\/s13311-021-01099-2_bib70","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nature07534","article-title":"Mitofusin 2 tethers endoplasmic reticulum to mitochondria","volume":"456","author":"de Brito","year":"2008","journal-title":"Nature"},{"key":"10.1007\/s13311-021-01099-2_bib71","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1073\/pnas.1810932116","article-title":"Altered interplay between endoplasmic reticulum and mitochondria in Charcot-Marie-Tooth type 2A neuropathy","volume":"116","author":"Bernard-Marissal","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01099-2_bib72","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature25486","article-title":"Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis","volume":"554","author":"Wong","year":"2018","journal-title":"Nature"},{"key":"10.1007\/s13311-021-01099-2_bib73","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1091\/mbc.11.2.467","article-title":"Rab7: a key to lysosome biogenesis","volume":"11","author":"Bucci","year":"2000","journal-title":"Mol Biol Cell"},{"key":"10.1007\/s13311-021-01099-2_bib74","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1074\/jbc.272.7.4391","article-title":"Role of the small GTPase Rab7 in the late endocytic pathway","volume":"272","author":"Vitelli","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-021-01099-2_bib75","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S0960-9822(01)00531-0","article-title":"The Rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors","volume":"11","author":"Jordens","year":"2001","journal-title":"Curr Biol"},{"key":"10.1007\/s13311-021-01099-2_bib76","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.neuron.2006.08.018","article-title":"Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway","volume":"52","author":"Deinhardt","year":"2006","journal-title":"Neuron"},{"key":"10.1007\/s13311-021-01099-2_bib77","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/hmg\/ddp567","article-title":"Disease mutations in Rab7 result in unregulated nucleotide exchange and inappropriate activation","volume":"19","author":"McCray","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-021-01099-2_bib78","doi-asserted-by":"crossref","unstructured":"Cioni, J. M., Lin, J. Q., Holtermann, A. V., Koppers, M., Jakobs, M. A. H., Azizi, A., Turner-Bridger, B., Shigeoka, T., Franze, K., Harris, W. A. & Holt, C. E. Late Endosomes Act as mRNA Translation Platforms and Sustain Mitochondria in Axons. Cell176, 56\u201372 e15 (2019).","DOI":"10.1016\/j.cell.2018.11.030"},{"key":"10.1007\/s13311-021-01099-2_bib79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.expneurol.2012.01.010","article-title":"Overlapping molecular pathological themes link Charcot-Marie-Tooth neuropathies and hereditary spastic paraplegias","volume":"246","author":"Timmerman","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-021-01099-2_bib80","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1093\/brain\/awu287","article-title":"Membrane-shaping disorders: a common pathway in axon degeneration","volume":"137","author":"Hubner","year":"2014","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01099-2_bib81","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fnins.2020.00048","article-title":"Axonal Endoplasmic Reticulum Dynamics and Its Roles in Neurodegeneration","volume":"14","author":"Ozturk","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1007\/s13311-021-01099-2_bib82","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11910-019-0930-2","article-title":"Update on the Genetics of Spastic Paraplegias","volume":"19","author":"Boutry","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1007\/s13311-021-01099-2_bib83","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fmolb.2019.00161","article-title":"The Role of RNA Binding Proteins for Local mRNA Translation: Implications in Neurological Disorders","volume":"6","author":"Thelen","year":"2019","journal-title":"Front Mol Biosci"},{"key":"10.1007\/s13311-021-01099-2_bib84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.nbd.2015.07.006","article-title":"Paclitaxel inhibits mRNA transport in axons","volume":"82","author":"Bobylev","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-021-01099-2_bib85","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/jnnp-2018-318834","article-title":"Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development","volume":"90","author":"Juneja","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01099-2_bib86","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0896-6273(00)80128-2","article-title":"A transgenic rat model of Charcot-Marie-Tooth disease","volume":"16","author":"Sereda","year":"1996","journal-title":"Neuron"},{"key":"10.1007\/s13311-021-01099-2_bib87","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1007\/s12035-020-02081-3","article-title":"Animal Models of CMT2A: State-of-art and Therapeutic Implications","volume":"57","author":"De Gioia","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1007\/s13311-021-01099-2_bib88","doi-asserted-by":"crossref","unstructured":"Stelten, B. M. L. et al. Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start. Neurology 92, e83-e95 (2019).","DOI":"10.1212\/WNL.0000000000006731"},{"key":"10.1007\/s13311-021-01099-2_bib89","doi-asserted-by":"crossref","unstructured":"Kuriyama, M., Tokimura, Y., Fujiyama, J., Utatsu, Y. & Osame, M. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J Neurol Sci 125, 22-28 (1994).","DOI":"10.1016\/0022-510X(94)90237-2"},{"key":"10.1007\/s13311-021-01099-2_bib90","doi-asserted-by":"crossref","unstructured":"Andersson, H. C., Marble, M. & Shapira, E. Long-term outcome in treated combined methylmalonic acidemia and homocystinemia. Genet Med 1, 146-150 (1999).","DOI":"10.1097\/00125817-199905000-00006"},{"key":"10.1007\/s13311-021-01099-2_bib91","doi-asserted-by":"crossref","unstructured":"Enns, G. M. et al. Progressive neurological deterioration and MRI changes in cblC methylmalonic acidaemia treated with hydroxocobalamin. J Inherit Metab Dis 22, 599-607 (1999).","DOI":"10.1023\/A:1005517727451"},{"key":"10.1007\/s13311-021-01099-2_bib92","doi-asserted-by":"crossref","unstructured":"Bartholomew, D. W. et al. Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuria. J Pediatr 112, 32-39 (1988).","DOI":"10.1016\/S0022-3476(88)80114-8"},{"key":"10.1007\/s13311-021-01099-2_bib93","doi-asserted-by":"crossref","unstructured":"Uziel, G., Garavaglia, B., Ciceri, E., Moroni, I. & Rimoldi, M. Riboflavin-responsive glutaric aciduria type II presenting as a leukodystrophy. Pediatr Neurol 13, 333-335 (1995).","DOI":"10.1016\/0887-8994(95)00187-5"},{"key":"10.1007\/s13311-021-01099-2_bib94","doi-asserted-by":"crossref","unstructured":"Plantone, D., Pardini, M. & Rinaldi, G. Riboflavin in Neurological Diseases: A Narrative Review. Clin Drug Investig 41, 513-527 (2021).","DOI":"10.1007\/s40261-021-01038-1"},{"key":"10.1007\/s13311-021-01099-2_bib95","doi-asserted-by":"crossref","unstructured":"De Biase, I. et al. Diagnosis, Treatment, and Clinical Outcome of Patients with Mitochondrial Trifunctional Protein\/Long-Chain 3-Hydroxy Acyl-CoA Dehydrogenase Deficiency. JIMD Rep 31, 63-71 (2017).","DOI":"10.1007\/8904_2016_558"},{"key":"10.1007\/s13311-021-01099-2_bib96","doi-asserted-by":"crossref","unstructured":"Chelban, V. et al. PDXK mutations cause polyneuropathy responsive to pyridoxal 5'-phosphate supplementation. Ann Neurol 86, 225-240 (2019).","DOI":"10.1002\/ana.25524"},{"key":"10.1007\/s13311-021-01099-2_bib97","doi-asserted-by":"crossref","unstructured":"Ortiz, A. et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 123, 416-427 (2018).","DOI":"10.1016\/j.ymgme.2018.02.014"},{"key":"10.1007\/s13311-021-01099-2_bib98","doi-asserted-by":"crossref","unstructured":"Germain, D. P. et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet 96, 107-117 (2019).","DOI":"10.1111\/cge.13546"},{"key":"10.1007\/s13311-021-01099-2_bib99","doi-asserted-by":"crossref","unstructured":"Gibberd, F. B., Billimoria, J. D., Page, N. G. & Retsas, S. Heredopathia atactica polyneuritiformis (refsum's disease) treated by diet and plasma-exchange. Lancet 1, 575-578 (1979).","DOI":"10.1016\/S0140-6736(79)91005-5"},{"key":"10.1007\/s13311-021-01099-2_bib100","unstructured":"Moser, H. W. et al. Therapeutic trial of plasmapheresis in Refsum disease and in Fabry disease. Birth Defects Orig Artic Ser 16, 491-497 (1980)."},{"key":"10.1007\/s13311-021-01099-2_bib101","doi-asserted-by":"crossref","unstructured":"Van Calcar, S. C. et al. Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): An evidence- and consensus-based approach. Mol Genet Metab 131, 23-37 (2020).","DOI":"10.1016\/j.ymgme.2020.10.001"},{"key":"10.1007\/s13311-021-01099-2_bib102","doi-asserted-by":"crossref","unstructured":"Marce-Grau, A., Marti-Sanchez, L., Baide-Mairena, H., Ortigoza-Escobar, J. D. & Perez-Duenas, B. Genetic defects of thiamine transport and metabolism: A review of clinical phenotypes, genetics, and functional studies. J Inherit Metab Dis 42, 581-597 (2019).","DOI":"10.1002\/jimd.12125"},{"key":"10.1007\/s13311-021-01099-2_bib103","doi-asserted-by":"crossref","unstructured":"Will, E. J. & Bijvoet, O. L. Primary oxalosis: clinical and biochemical response to high-dose pyridoxine therapy. Metabolism 28, 542-548 (1979).17Albers, J. W. & Fink, J. K. Porphyric neuropathy. Muscle Nerve 30, 410-422 (2004).","DOI":"10.1016\/0026-0495(79)90195-1"},{"key":"10.1007\/s13311-021-01099-2_bib104","doi-asserted-by":"crossref","unstructured":"Albers, J. W. & Fink, J. K. Porphyric neuropathy. Muscle Nerve 30, 410-422 (2004).","DOI":"10.1002\/mus.20137"},{"key":"10.1007\/s13311-021-01099-2_bib105","doi-asserted-by":"crossref","unstructured":"Balwani, M. et al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med 382, 2289-2301 (2020).","DOI":"10.1056\/NEJMoa1913147"},{"key":"10.1007\/s13311-021-01099-2_bib106","doi-asserted-by":"crossref","unstructured":"Lindstedt, S., Holme, E., Lock, E. A., Hjalmarson, O. & Strandvik, B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340, 813-817 (1992).","DOI":"10.1016\/0140-6736(92)92685-9"},{"key":"10.1007\/s13311-021-01099-2_bib107","unstructured":"Burnett, J. R., Hooper, A. J. & Hegele, R. A. in GeneReviews((R))\u00a0 \u00a0(eds M. P. Adam et al.)\u00a0 (1993)."},{"key":"10.1007\/s13311-021-01099-2_bib108","doi-asserted-by":"crossref","unstructured":"Martinelli, D. et al. MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. Brain 136, 872-881 (2013).","DOI":"10.1093\/brain\/awt012"},{"key":"10.1007\/s13311-021-01099-2_bib109","doi-asserted-by":"crossref","unstructured":"Hashizume, A., Fischbeck, K. H., Pennuto, M., Fratta, P. & Katsuno, M. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA). J Neurol Neurosurg Psychiatry 91, 1085-1091 (2020).","DOI":"10.1136\/jnnp-2020-322949"},{"key":"10.1007\/s13311-021-01099-2_bib110","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/85879","article-title":"Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I","volume":"27","author":"Dawkins","year":"2001","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-021-01099-2_bib111","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85817","article-title":"SPTLC1 is mutated in hereditary sensory neuropathy, type 1","volume":"27","author":"Bejaoui","year":"2001","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-021-01099-2_bib112","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/brain\/awh712","article-title":"Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I)","volume":"129","author":"Houlden","year":"2006","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01099-2_bib113","doi-asserted-by":"crossref","first-page":"11178","DOI":"10.1074\/jbc.M109.092973","article-title":"Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids","volume":"285","author":"Penno","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-021-01099-2_bib114","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1172\/JCI57549","article-title":"Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1","volume":"121","author":"Garofalo","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-021-01099-2_bib115","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1212\/WNL.0000000000006811","article-title":"Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1","volume":"92","author":"Fridman","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01099-2_bib116","doi-asserted-by":"crossref","unstructured":"Cortese, A., Zhu, Y., Rebelo, A. P., Negri, S., Courel, S., Abreu, L., Bacon, C. J., Bai, Y., Bis-Brewer, D. M., Bugiardini, E., Buglo, E., Danzi, M. C., Feely, S. M. E., Athanasiou-Fragkouli, A., Haridy, N. A., Inherited Neuropathy, C., Isasi, R., Khan, A., Laura, M., Magri, S., Pipis, M., Pisciotta, C., Powell, E., Rossor, A. M., Saveri, P., Sowden, J. E., Tozza, S., Vandrovcova, J., Dallman, J., Grignani, E., Marchioni, E., Scherer, S. S., Tang, B., Lin, Z., Al-Ajmi, A., Schule, R., Synofzik, M., Maisonobe, T., Stojkovic, T., Auer-Grumbach, M., Abdelhamed, M. A., Hamed, S. A., Zhang, R., Manganelli, F., Santoro, L., Taroni, F., Pareyson, D., Houlden, H., Herrmann, D. N., Reilly, M. M., Shy, M. E., Zhai, R. G. & Zuchner, S. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet52, 473\u2013481 (2020).","DOI":"10.1038\/s41588-020-0649-7"},{"key":"10.1007\/s13311-021-01099-2_bib117","doi-asserted-by":"crossref","unstructured":"Chalk, C., Benstead, T. J. & Moore, F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev, CD004572 (2007).","DOI":"10.1002\/14651858.CD004572.pub2"},{"key":"10.1007\/s13311-021-01099-2_bib118","doi-asserted-by":"crossref","unstructured":"El Fissi, N., Rojo, M., Aouane, A., Karatas, E., Poliacikova, G., David, C., Royet, J. & Rival, T. Mitofusin gain and loss of function drive pathogenesis in Drosophila models of CMT2A neuropathy. EMBO Rep19 (2018).","DOI":"10.15252\/embr.201745241"},{"key":"10.1007\/s13311-021-01099-2_bib119","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nature20156","article-title":"Correcting mitochondrial fusion by manipulating mitofusin conformations","volume":"540","author":"Franco","year":"2016","journal-title":"Nature"},{"key":"10.1007\/s13311-021-01099-2_bib120","doi-asserted-by":"crossref","unstructured":"Dang, X., Zhang, L., Franco, A., Li, J., Rocha, A. G., Devanathan, S., Dolle, R. E., Bernstein, P. R. & Dorn, G. W., 2nd. Discovery of 6-Phenylhexanamide Derivatives as Potent Stereoselective Mitofusin Activators for the Treatment of Mitochondrial Diseases. J Med Chem63, 7033\u20137051 (2020).","DOI":"10.1021\/acs.jmedchem.0c00366"},{"key":"10.1007\/s13311-021-01099-2_bib121","doi-asserted-by":"crossref","unstructured":"Franco, A., Dang, X., Walton, E. K., Ho, J. N., Zablocka, B., Ly, C., Miller, T. M., Baloh, R. H., Shy, M. E., Yoo, A. S. & Dorn, G. W., 2nd. Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A. Elife9 (2020).","DOI":"10.7554\/eLife.61119"},{"key":"10.1007\/s13311-021-01099-2_bib122","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41467-021-21699-y","article-title":"Neuropathy-causing TRPV4 mutations disrupt TRPV4-RhoA interactions and impair neurite extension","volume":"12","author":"McCray","year":"2021","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-021-01099-2_bib123","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/s41467-020-16411-5","article-title":"TRPV4 disrupts mitochondrial transport and causes axonal degeneration via a CaMKII-dependent elevation of intracellular Ca(2)","volume":"11","author":"Woolums","year":"2020","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-021-01099-2_bib124","unstructured":"McCray, B. A., Schindler, A., Hoover-Fong, J. E. & Sumner, C. J. in GeneReviews((R)) (eds M. P. Adam et al.) (1993)."},{"key":"10.1007\/s13311-021-01099-2_bib125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40256-018-00320-6","article-title":"Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects","volume":"19","author":"Goyal","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1007\/s13311-021-01099-2_bib126","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.1223899","article-title":"dSarm\/Sarm1 is required for activation of an injury-induced axon death pathway","volume":"337","author":"Osterloh","year":"2012","journal-title":"Science"},{"key":"10.1007\/s13311-021-01099-2_bib127","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1126\/science.1258366","article-title":"SARM1 activation triggers axon degeneration locally via NAD(+) destruction","volume":"348","author":"Gerdts","year":"2015","journal-title":"Science"},{"key":"10.1007\/s13311-021-01099-2_bib128","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.cub.2006.09.014","article-title":"Microtubule acetylation promotes kinesin-1 binding and transport","volume":"16","author":"Reed","year":"2006","journal-title":"Curr Biol"},{"key":"10.1007\/s13311-021-01099-2_bib129","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nm.2396","article-title":"HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease","volume":"17","author":"d'Ydewalle","year":"2011","journal-title":"Nat Med"},{"key":"10.1007\/s13311-021-01099-2_bib130","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/brain\/awx375","article-title":"HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease","volume":"141","author":"Benoy","year":"2018","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01099-2_bib131","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cell"},{"key":"10.1007\/s13311-021-01099-2_bib132","doi-asserted-by":"crossref","unstructured":"Rossaert, E. & Van Den Bosch, L. HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT. Brain Res1733, 146692 (2020).","DOI":"10.1016\/j.brainres.2020.146692"},{"key":"10.1007\/s13311-021-01099-2_bib133","doi-asserted-by":"crossref","unstructured":"Picci, C., Wong, V. S. C., Costa, C. J., McKinnon, M. C., Goldberg, D. C., Swift, M., Alam, N. M., Prusky, G. T., Shen, S., Kozikowski, A. P., Willis, D. E. & Langley, B. HDAC6 inhibition promotes alpha-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice. Exp Neurol328, 113281 (2020).","DOI":"10.1016\/j.expneurol.2020.113281"},{"key":"10.1007\/s13311-021-01099-2_bib134","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nature05853","article-title":"HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS","volume":"447","author":"Pandey","year":"2007","journal-title":"Nature"},{"key":"10.1007\/s13311-021-01099-2_bib135","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01099-2_bib136","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/14712598.2018.1416089","article-title":"AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials","volume":"18","author":"Hardcastle","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1007\/s13311-021-01099-2_bib137","doi-asserted-by":"crossref","unstructured":"Morelli, K. H., Hatton, C. L., Harper, S. Q. & Burgess, R. W. Gene therapies for axonal neuropathies: Available strategies, successes to date, and what to target next. Brain Res1732, 146683 (2020).","DOI":"10.1016\/j.brainres.2020.146683"},{"key":"10.1007\/s13311-021-01099-2_bib138","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1172\/JCI124194","article-title":"Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model","volume":"129","author":"Zhou","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-021-01099-2_bib139","doi-asserted-by":"crossref","unstructured":"Bomont, P., Cavalier, L., Blondeau, F., Ben Hamida, C., Belal, S., Tazir, M., Demir, E., Topaloglu, H., Korinthenberg, R., Tuysuz, B., Landrieu, P., Hentati, F. & Koenig, M. The gene encoding gigaxonin, a new member of the cytoskeletal BTB\/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet26, 370\u2013374 (2000).","DOI":"10.1038\/81701"},{"key":"10.1007\/s13311-021-01099-2_bib140","doi-asserted-by":"crossref","unstructured":"Bailey, R. M., Armao, D., Nagabhushan Kalburgi, S. & Gray, S. J. Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy. Mol Ther Methods Clin Dev9, 160\u2013171 (2018).","DOI":"10.1016\/j.omtm.2018.02.005"},{"key":"10.1007\/s13311-021-01099-2_bib141","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1172\/JCI130600","article-title":"Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models","volume":"129","author":"Morelli","year":"2019","journal-title":"J Clin Invest"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01099-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300702X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300702X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:42:28Z","timestamp":1761806548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792300702X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":141,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S187874792300702X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01099-2","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01099-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}